Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares Silver Trust (SLV) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares Silver TrustTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares Silver Trust — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while iShares Silver Trust trades at $59.64. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.

AMLXSLV
Market Cap
$2.64B
Sector
Health
52-Week High
$24.19$105.57
52-Week Low
$7.82$33.89
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

iShares Silver Trust

SLV trades at $59.45, showing minimal daily movement with a 0.07% gain. The technical outlook is bullish with strong moving average support, though RSI levels suggest potential overbought conditions near-term. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, with the metal recovering from earlier 2026 declines.

Silver's investment case remains compelling due to structural supply constraints and growing industrial demand, particularly from technology sectors. Key risks include Federal Reserve policy uncertainty and dollar strength, while technical resistance near $60 presents immediate price challenges. The metal's volatility requires careful position sizing despite positive long-term fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares Silver Trust

The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.

Read more on SLV